Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Clinical trial NCT03213002 · RECRUITING
Trial details
- NCT number
- NCT03213002
- Sponsor
- Northwell Health
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-13
- Primary completion
- 2028-06-01
- Enrollment
- 67
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.